drugset
drugset / Trial / NCT00411905

Bortezomib and Low Dose Cytarabine in the Treatment of High-risk Myelodysplastic Syndromes

NCT00411905 ↗

Phase 1/2 Completed 45 enrolled Groupe Francophone des Myelodysplasies Johnson & Johnson · collab
NaSingle-groupOpen-labelTreatment

Summary

We are evaluating the efficacy of the association of Low dose Cytarabine in association with Bortezomib in the treatment of patients diagnosed with high risk Myelodysplastic syndromes. Our aim is to decrease transfusion requirements and if possible induce a complete or at least a partial remission.

Timeline

Start
2006-06-01
Primary completion
2010-07-08
Completion
2011-08-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Bortezomib Small molecule 1.5 mg/m2 —

Indications

myelodysplastic syndrome